Compile Data Set for Download or QSAR
Report error Found 202 Enz. Inhib. hit(s) with all data for entry = 12111
TargetEpidermal growth factor receptor [1-745,751-1210,T790M,C797S](Homo sapiens (Human))
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679664(US20240182487, Compound 63)
Affinity DataIC50: 0.200nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M,C797S](Homo sapiens (Human))
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679658(US20240182487, Compound 1)
Affinity DataIC50: 0.220nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M,C797S](Homo sapiens (Human))
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679663(US20240182487, Compound 62)
Affinity DataIC50: 0.5nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679677(US20240182487, Compound 76)
Affinity DataIC50: 1.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679672(US20240182487, Compound 71)
Affinity DataIC50: 1.60nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679658(US20240182487, Compound 1)
Affinity DataIC50: 2.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679677(US20240182487, Compound 76)
Affinity DataIC50: 2.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679671(US20240182487, Compound 70)
Affinity DataIC50: 2.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679677(US20240182487, Compound 76)
Affinity DataIC50: 2.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679672(US20240182487, Compound 71)
Affinity DataIC50: 2.40nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679664(US20240182487, Compound 63)
Affinity DataIC50: 2.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679675(US20240182487, Compound 74)
Affinity DataIC50: 2.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679679(US20240182487, Compound 78)
Affinity DataIC50: 2.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679671(US20240182487, Compound 70)
Affinity DataIC50: 2.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679696(US20240182487, Compound 97)
Affinity DataIC50: 3.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679677(US20240182487, Compound 76)
Affinity DataIC50: 3.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679696(US20240182487, Compound 97)
Affinity DataIC50: 3.40nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679672(US20240182487, Compound 71)
Affinity DataIC50: 3.70nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679672(US20240182487, Compound 71)
Affinity DataIC50: 3.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M,C797S](Homo sapiens (Human))
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679666(US20240182487, Compound 65)
Affinity DataIC50: 3.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679675(US20240182487, Compound 74)
Affinity DataIC50: 4nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679687(US20240182487, Compound 88)
Affinity DataIC50: 4.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679658(US20240182487, Compound 1)
Affinity DataIC50: 4.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679663(US20240182487, Compound 62)
Affinity DataIC50: 4.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679692(US20240182487, Compound 93)
Affinity DataIC50: 4.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679696(US20240182487, Compound 97)
Affinity DataIC50: 4.5nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679658(US20240182487, Compound 1)
Affinity DataIC50: 4.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679685(US20240182487, Compound 86)
Affinity DataIC50: 4.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M,C797S](Homo sapiens (Human))
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679661(US20240182487, Compound 16)
Affinity DataIC50: 5.10nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679679(US20240182487, Compound 78)
Affinity DataIC50: 5.30nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679671(US20240182487, Compound 70)
Affinity DataIC50: 5.30nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679681(US20240182487, Compound 82)
Affinity DataIC50: 5.40nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679675(US20240182487, Compound 74)
Affinity DataIC50: 5.70nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679663(US20240182487, Compound 62)
Affinity DataIC50: 5.70nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679664(US20240182487, Compound 63)
Affinity DataIC50: 5.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679671(US20240182487, Compound 70)
Affinity DataIC50: 5.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679682(US20240182487, Compound 83)
Affinity DataIC50: 6nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679679(US20240182487, Compound 78)
Affinity DataIC50: 6.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679658(US20240182487, Compound 1)
Affinity DataIC50: 6.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679692(US20240182487, Compound 93)
Affinity DataIC50: 7.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679664(US20240182487, Compound 63)
Affinity DataIC50: 7.70nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679675(US20240182487, Compound 74)
Affinity DataIC50: 8.30nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679689(US20240182487, Compound 90)
Affinity DataIC50: 8.60nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679685(US20240182487, Compound 86)
Affinity DataIC50: 8.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679664(US20240182487, Compound 63)
Affinity DataIC50: 8.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679693(US20240182487, Compound 94)
Affinity DataIC50: 9.20nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679696(US20240182487, Compound 97)
Affinity DataIC50: 9.70nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679681(US20240182487, Compound 82)
Affinity DataIC50: 9.80nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679693(US20240182487, Compound 94)
Affinity DataIC50: 9.90nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-745,751-1210,T790M,C797S](Homo sapiens (Human))
Blossomhill Therapeutics

US Patent
LigandPNGBDBM679660(US20240182487, Compound 3)
Affinity DataIC50: 10.2nMAssay Description:Biochemical Assays for Inhibition of Wild-Type and Mutant EGFRs.The inhibitory activities against EGFR WT, EGFR Δ752-759 mutant, EGFR Δ746-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2024
Entry Details
US Patent

Displayed 1 to 50 (of 202 total ) | Next | Last >>
Jump to: